Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$1.12 USD
+0.02 (1.82%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $1.12 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALLO 1.12 +0.02(1.82%)
Will ALLO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALLO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALLO
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?
ALLO: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus
Other News for ALLO
ALLO: JMP Securities Reiterates Market Perform Rating | ALLO Stock News
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday
Allogene Therapeutics (ALLO) Downgraded by JP Morgan to Neutral | ALLO Stock News
Allogene Therapeutics (ALLO) Faces Price Target Cut Amid Study Setback
Allogene Resets Clinical Course After Patient Death In Lymphoma Study